| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer | Frank Vinluan | 07/27/20 | Europe |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod | Frank Vinluan | 04/22/20 | New York |
| Seattle Genetics Gets Early FDA Nod for Breast Cancer Combo Drug | Sarah de Crescenzo | 04/18/20 | Seattle |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal | Sarah de Crescenzo | 02/20/20 | Seattle |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More | Sarah de Crescenzo | 10/25/19 | National |
| SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study | Sarah de Crescenzo | 10/21/19 | Seattle |
| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts | Frank Vinluan | 07/18/19 | National |
| Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More | Ben Fidler | 03/29/19 | National |
| VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic | Frank Vinluan | 10/01/18 | San Diego |
| Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies | Frank Vinluan | 03/29/18 | Boston |
| Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks | Ben Fidler | 03/23/18 | National |
| Unum, Homology Plan IPOs, as Unum Reveals Two Patient Deaths | Frank Vinluan | 03/05/18 | Boston |
| Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More | Frank Vinluan | 02/02/18 | National |
| Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug | Ben Fidler | 01/31/18 | Seattle |
| ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More | Alex Lash | 12/11/17 | National |
| Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi | Ben Fidler | 11/10/17 | National |
| Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More | Alex Lash | 06/30/17 | National |
| Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More | Alex Lash | 06/23/17 | National |
| SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others | Frank Vinluan | 06/19/17 | Seattle |
